EVH

SEC source: 0001628908-22-000158 · wf-form4_167027751161266.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 627,379

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.997 to $28.890, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000158 · wf-form4_167027751161266.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 736,479

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000156 · wf-form4_166925103286679.xml · derivative · entry 3

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,040

Underlying: Class A Common Stock · 75,000 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 16, 2022.

F4 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2016, and December 1, 2017.

SEC source: 0001628908-22-000156 · wf-form4_166925103286679.xml · nonDerivative · entry 2

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 422,037

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 16, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.38 to $27.10, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000156 · wf-form4_166925103286679.xml · nonDerivative · entry 1

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,037

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 16, 2022.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000143 · wf-form4_166752582727331.xml · derivative · entry 7

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,060

Underlying: Class A Common Stock · 110,000 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F8 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2015 and December 1, 2016.

SEC source: 0001628908-22-000143 · wf-form4_166752582727331.xml · nonDerivative · entry 5

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 626,479

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000143 · wf-form4_166752582727331.xml · nonDerivative · entry 4

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 627,156

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.101 to $30.780, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000143 · wf-form4_166752582727331.xml · nonDerivative · entry 3

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 640,929

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.008 to $30.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000143 · wf-form4_166752582727331.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 698,367

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.56 to $29.00, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000143 · wf-form4_166752582727331.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 736,479

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2022.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

F3 · balance_after: Since the date of the reporting person's last ownership report, he transferred 125,955 shares of EVH Class A common stock pursuant to a domestic relations order.

SEC source: 0001628908-22-000124 · wf-form4_166206612611091.xml · nonDerivative · entry 1

Scott Cheryl · CIK 0001656979 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,104

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $36.79, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000122 · wf-form4_166145979171552.xml · derivative · entry 7

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,273

Underlying: Class A Common Stock · 50,000 shares

Expires 2028-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The Class A Common Stock Option exercised vested on February 1, 2019.

SEC source: 0001628908-22-000122 · wf-form4_166145979171552.xml · nonDerivative · entry 4

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 752,434

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.58, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000122 · wf-form4_166145979171552.xml · nonDerivative · entry 3

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 802,434

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000122 · wf-form4_166145979171552.xml · derivative · entry 6

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,060

Underlying: Class A Common Stock · 150,000 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The Class A Common Stock Options exercised vested on December 1, 2014 and December 1, 2015.

SEC source: 0001628908-22-000122 · wf-form4_166145979171552.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 752,434

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.53 to $36.24, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000122 · wf-form4_166145979171552.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 902,434

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000118 · wf-form4_166086027820113.xml · nonDerivative · entry 1

Johnson John Paul · CIK 0001782040 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,329

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.11 to $34.22, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000120 · wf-form4_166086052563047.xml · nonDerivative · entry 1

DUFFY MARY BRIDGET · CIK 0001570881 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,450

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.080 to $33.165, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000113 · wf-form4_166068494670469.xml · derivative · entry 3

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 14,335 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Class A Common Stock Options exercised vested on March 1, 2017, March 1, 2018, March 1, 2019, and March 1, 2020.

SEC source: 0001628908-22-000113 · wf-form4_166068494670469.xml · nonDerivative · entry 2

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,103

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.86 to $35.10, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000113 · wf-form4_166068494670469.xml · nonDerivative · entry 1

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,438

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000100 · wf-form4_165964981345690.xml · nonDerivative · entry 1

Shams Aammaad · CIK 0001815354 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,884

F1 · security: Represents restricted stock units granted to Mr. Shams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest at a rate of 34% on August 1, 2023, and 33% on August 1, 2024, and August 1, 2025.

F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000090 · wf-form4_165706320470171.xml · nonDerivative · entry 1

Tutewohl Steve · CIK 0001811845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,170

F1 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000079 · wf-form4_165515885500799.xml · nonDerivative · entry 1

KECK KIM · CIK 0001818332 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,224

F1 · security: Represents restricted stock units granted to Ms. Keck pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000077 · wf-form4_165515859154736.xml · nonDerivative · entry 1

Holder Diane · CIK 0001642976 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,091

F1 · security: Represents restricted stock units granted to Ms. Holder pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000075 · wf-form4_165515833918728.xml · nonDerivative · entry 1

Farner David · CIK 0001642786 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,091

F1 · security: Represents restricted stock units granted to Mr. Farner pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000069 · wf-form4_165515751161739.xml · nonDerivative · entry 1

GRUA PETER J · CIK 0001242813 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,619

F1 · security: Represents restricted stock units granted to Mr. Grua pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000085 · wf-form4_165515960710905.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 752,434

F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

SEC source: 0001628908-22-000085 · wf-form4_165515960710905.xml · nonDerivative · entry 1

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 756,434

F1 · security: Represents restricted stock units granted to Mr. Williams pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000071 · wf-form4_165515783970435.xml · nonDerivative · entry 1

Barbarosh Craig A. · CIK 0001472457 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,198

F1 · security: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000073 · wf-form4_165515805560834.xml · nonDerivative · entry 1

DUFFY MARY BRIDGET · CIK 0001570881 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,950

F1 · security: Represents restricted stock units granted to Dr. Duffy pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000083 · wf-form4_165515932459032.xml · nonDerivative · entry 1

Sotunde Tunde · CIK 0001891237 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,969

F1 · security: Represents restricted stock units granted to Dr. Sotunde pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000081 · wf-form4_165515911579815.xml · nonDerivative · entry 1

Scott Cheryl · CIK 0001656979 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,204

F1 · security: Represents restricted stock units granted to Ms. Scott pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2 · shares: Securities vest on the earlier of June 9, 2023 and the date of the company's 2023 annual meeting, subject to the reporting person's continued service on the vesting date.

SEC source: 0001628908-22-000041 · wf-form4_164644541632644.xml · nonDerivative · entry 3

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,103

F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of leveraged stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000045 · wf-form4_164644567295512.xml · nonDerivative · entry 2

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 422,037

F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of leveraged stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table I of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000043 · wf-form4_164644552440218.xml · nonDerivative · entry 3

Johnson John Paul · CIK 0001782040 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,763

F4 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of leveraged stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000052 · wf-form4_164669093397916.xml · nonDerivative · entry 1

Tutewohl Steve · CIK 0001811845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,421

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.78, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000054 · wf-form4_164696201693474.xml · nonDerivative · entry 2

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 750,730

F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of leveraged stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table I of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000041 · wf-form4_164644541632644.xml · derivative · entry 4

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 53,789 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Leveraged Stock Units vested on March 2, 2022.

F6 · derivative.expiration_date: These Leveraged Stock Units do not expire.

SEC source: 0001628908-22-000041 · wf-form4_164644541632644.xml · nonDerivative · entry 2

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,152

F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000041 · wf-form4_164644541632644.xml · nonDerivative · entry 1

Weinberg Jonathan · CIK 0001642833 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of the leveraged stock units granted to Mr. Weinberg on March 1, 2019, based on the cumulative performance of the Issuer's Class A Common Stock.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000045 · wf-form4_164644567295512.xml · derivative · entry 3

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 286,867 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Leveraged Stock Units vested on March 2, 2022.

F5 · derivative.expiration_date: These Leveraged Stock Units do not expire.

SEC source: 0001628908-22-000045 · wf-form4_164644567295512.xml · nonDerivative · entry 1

Blackley Seth · CIK 0001643346 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 551,415

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of the leveraged stock units granted to Mr. Blackley on March 1, 2019, based on the cumulative performance of the Issuer's Class A Common Stock.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table I of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000047 · wf-form4_164644584510521.xml · nonDerivative · entry 1

Tutewohl Steve · CIK 0001811845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,339

F1 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000043 · wf-form4_164644552440218.xml · derivative · entry 4

Johnson John Paul · CIK 0001782040 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 71,716 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Leveraged Stock Units vested on March 2, 2022.

F6 · derivative.expiration_date: The Leveraged Stock Units do not expire.

SEC source: 0001628908-22-000043 · wf-form4_164644552440218.xml · nonDerivative · entry 2

Johnson John Paul · CIK 0001782040 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,107

F3 · shares: This number represents shares of Class A Common Stock withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000043 · wf-form4_164644552440218.xml · nonDerivative · entry 1

Johnson John Paul · CIK 0001782040 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the vesting of the leveraged stock units granted to Mr. Johnson on March 1, 2019, based on the cumulative performance of the Issuer's Class A Common Stock.

F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

SEC source: 0001628908-22-000054 · wf-form4_164696201693474.xml · derivative · entry 4

WILLIAMS FRANK J · CIK 0001204938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 382,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Leveraged Stock Units vested on March 2, 2022.

F6 · derivative.expiration_date: These Leveraged Stock Units do not expire.